隶属于 sino biopharmaceutical ltd.
相关临床试验
14
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1995
进行中（未招募）
1
7.1%
已完成
1
7.1%
Enrolling By Invitation
1
7.1%
尚未招募
5
35.7%
招募中
5
35.7%
Unknown
1
7.1%
暂无批准数据
- AstraZeneca officially opened its sixth global strategic R&D center in Beijing's BioPark, marking the company's second facility in China alongside its Shanghai center. - The new facility will leverage Beijing's artificial intelligence capabilities and scientific ecosystem to accelerate development of innovative next-generation drugs. - The center will collaborate with AstraZeneca's Shanghai R&D facility to lead drug discovery and clinical development efforts, translating innovations into medicines. - The Beijing Economic-Technological Development Area hosts over 5,000 biopharmaceutical companies and has approved two innovative drugs and three medical devices since 2025.
- Beijing Tide Pharmaceutical has dosed the first patient in Phase II trials of TRD205, a first-in-class AT2R antagonist targeting chronic post-surgical neuropathic pain without opioid-related risks. - TRD205 works by selectively blocking AT2R receptors that trigger pain sensitization, addressing a condition affecting approximately 30 million surgical patients annually with limited effective treatment options. - The Phase II study will enroll 184 patients to evaluate pain score improvements, positioning TRD205 in a potential $10 billion market that includes future expansion into diabetic neuropathy and postherpetic neuralgia.
